Joe N. Kornegay, DVM, PhD, Diplomate ACVIM (Neurology), ACVP (hon) November 2019 Dr. Joe N. Kornegay, formerly Professor, Departments of Veterinary Integrative Biosciences and Veterinary Pathobiology, Texas A&M University and the Texas A&M Institute for Neuroscience (April 1, 2012 to June 1, 2019). After receiving his veterinary degree from Texas A&M, Dr. Kornegay spent three years in private practice in Ohio and Texas, followed by six years in residency (neurology and pathology) and graduate (Masters and PhD) training at the University of Georgia College of Veterinary Medicine. Upon completion of this training, he served on the faculty of the veterinary school at North Carolina State University for 11 years before moving to the University of Missouri. At Missouri, Dr. Kornegay principally served as an administrator, first jointly as clinical department chair and hospital director and later as dean. He joined the faculty of the medical school at the University of North Carolina at Chapel Hill in 2006 and moved to his most recent position as a professor in the veterinary school at Texas A&M University in 2012. While at Texas A&M, Dr. Kornegay also served as Director of the Texas A&M Institute for Preclinical Studies (TIPS), which is essentially a contract research organization based within the university. He is a diplomate and past president of the neurology specialty of the American College of Veterinary Internal Medicine (ACVIM), a past President and Chair of ACVIM's Board of Regents, and an honorary diplomate of the American College of Veterinary Pathologists (ACVP). Throughout his career as an academic clinician, Dr. Kornegay had responsibilities in both medical neurology and neurosurgery and also consulted in neuropathology. For the past 30-plus years, he has studied a spontaneous canine disease called golden retriever muscular dystrophy (GRMD) that serves as an animal model for Duchenne muscular dystrophy (DMD) of humans. Both conditions are X-linked, occurring due to mutations in the DMD gene. His research has defined key clinical and pathologic features of GRMD to both better understand disease pathogenesis and to also utilize these parameters in assessing treatment efficacy. In recent years, Dr. Kornegay’s laboratory and collaborators have studied various treatments (cell, genetic, and pharmacologic) in affected dogs. Results of these preclinical studies have guided use of similar treatment strategies in DMD patients. This research has largely been supported by the NIH, with funding also coming from industry and the Muscular Dystrophy Association.